MIP Diagnostics granted US patent on Preparation of Molecularly Imprinted Polymers (MIPs)
MIP Diagnostics Ltd today announces the grant of a patent for the Preparation of Molecularly Imprinted Polymers by the United States Patent and Trademark Office (USPTO).
NanoMIPs are, as the name suggests, nanostructured polymer particles typically containing a single binding site for their target. MIPs are a proven alternative to antibodies and offer many advantages over antibodies. They can also be fused to solid substrates, such as sensor surfaces, if required. Our proprietary technology includes a novel method to make nanoMIPs offering partners new IP opportunities.
The robust nature of MIPs and nanoMIPs make them ideal reagents for a wide range of applications including point-of-care diagnostics and in field-based testing. As they are synthetic polymers, MIPs can withstand harsh chemical environments such as extremes of pH, seawater, or high concentrations of organic solvents. In addition, MIPs have a very long shelf life, even at room temperature, which provides significant economic benefits and makes them ideal when cold chain environments cannot be guaranteed.
Overview of the Process Patented
US 10,189,934 B2 describes a polymerization process, typically a living radical polymerisation process, that is carried out in the presence of the template or target molecule, to produce molecularly imprinted polymers ("MIPs"). It is controlled so that the products are quite small so that they are soluble or form colloidal suspensions and typically contain just one imprint of, or binding site for, the target. The template substances, immobilized on the solid support, can often be re-used, further improving the efficiency of the process.
Application of the invention
MIPs have broad application as affinity reagents in; diagnostics, sensing, purification, separation and nalysis, and have been successfully created and deployed against all major target classes including peptides, proteins and other macromolecular structures, as well as smaller chemical entities such as drugs, their metabolites and commonly used biochemical species such as enzyme cofactors.
MIPs are synthesized in a laboratory and can be created in days. They are more cost-effective and much more stable than antibodies and other biologically-based affinity reagents, with a longer shelf-life and can be used in conditions where antibodies are unable to function.
Commenting on the patent, CEO Adrian Kinkaid said;
“Being granted this patent is a great boost for the business and demonstrates the uniqueness of our platform process which enables us to produce the best MIPs in the world, specifically tailored for a given application. It compliments and enhances our growth strategy particularly in the key USA market and allows us to push our plan for incorporation of MIPs in many key products in a wide range of fields including Oil & Gas exploration, Bioprocessing and Clinical diagnostics. We are continuing to expand rapidly and expect to grow our client base further, a client base which already comprises a number of global pharmaceutical companies, blue-chip clients from other fields and many biotech businesses.”